Metabolic & Weight Management
Cagrilintide
Also known as AM833 · long-acting amylin analog
Emerging researchSubcutaneous injectionNot FDA-approved; investigational. The cagrilintide-semaglutide combination (CagriSema) was submitted to the FDA in late 2025 but is not approved.
Cagrilintide is a long-acting analog of the pancreatic hormone amylin. By acting on amylin and calcitonin receptors, it promotes satiety, slows gastric emptying, and reduces food intake through mechanisms distinct from GLP-1. It has been studied alone and in a fixed-dose combination with semaglutide (investigationally known as CagriSema).
Studied / used for
- studied for weight management in obesity/overweight
- studied in combination with semaglutide for weight loss and type 2 diabetes
Commonly reported side effects
- nausea
- vomiting
- diarrhea
- constipation
- decreased appetite
- injection-site reactions
Emerging research. Active research; human evidence still developing. This reflects the strength of the research base, not effectiveness or a recommendation.
Not medical advice.
This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.